SOTAC PHARMACEUTICALS
|
SOTAC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.22 | 7.26 | 3.87 | 3.58 | 12.52 |
| CEPS(Rs) | 10.59 | 11.86 | 6.05 | 5.67 | 4.98 |
| DPS(Rs) | 0.20 | 0.10 | - | - | 2.00 |
| Book NAV/Share(Rs) | 53.28 | 48.19 | 40.96 | 12.41 | 28.79 |
| Tax Rate(%) | 27.63 | 16.59 | 9.70 | 41.78 | 38.68 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.67 | 16.43 | 8.01 | 9.44 | 8.44 |
| EBIT Margin(%) | 12.67 | 13.73 | 5.49 | 7.70 | 7.20 |
| Pre Tax Margin(%) | 8.59 | 11.15 | 3.82 | 5.07 | 6.42 |
| PAT Margin (%) | 6.22 | 9.30 | 3.45 | 2.95 | 3.94 |
| Cash Profit Margin (%) | 11.56 | 13.15 | 6.43 | 5.89 | 5.48 |
| Performance Ratios | |||||
| ROA(%) | 4.93 | 8.17 | 4.03 | 4.20 | 8.23 |
| ROE(%) | 11.23 | 18.83 | 12.96 | 27.53 | 63.16 |
| ROCE(%) | 13.26 | 16.40 | 10.22 | 21.50 | 31.31 |
| Asset Turnover(x) | 0.79 | 0.88 | 1.17 | 1.42 | 2.09 |
| Sales/Fixed Asset(x) | 1.54 | 1.84 | 2.65 | 3.34 | 4.12 |
| Working Capital/Sales(x) | 5.24 | 5.46 | 6.14 | 58.39 | -42.31 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.65 | 0.54 | 0.38 | 0.30 | 0.24 |
| Receivable days | 120.89 | 110.52 | 72.11 | 63.58 | 45.25 |
| Inventory Days | 85.33 | 70.03 | 55.63 | 44.84 | 25.51 |
| Payable days | 130.52 | 127.81 | 124.45 | 143.83 | 106.65 |
| Valuation Parameters | |||||
| PER(x) | 20.93 | 16.35 | 31.23 | - | - |
| PCE(x) | 10.32 | 10.01 | 20.02 | - | - |
| Price/Book(x) | 2.05 | 2.46 | 2.95 | - | - |
| Yield(%) | 0.18 | 0.08 | - | - | - |
| EV/Net Sales(x) | 1.55 | 1.74 | 1.49 | 0.26 | 0.13 |
| EV/Core EBITDA(x) | 8.62 | 9.89 | 17.63 | 2.66 | 1.51 |
| EV/EBIT(x) | 12.25 | 12.66 | 27.21 | 3.42 | 1.83 |
| EV/CE(x) | 1.63 | 1.79 | 2.21 | 0.49 | 0.27 |
| M Cap / Sales | 1.19 | 1.32 | 1.29 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.51 | -3.94 | 34.00 | 5.92 | 49.77 |
| Core EBITDA Growth(%) | 3.99 | 99.19 | 14.83 | 19.94 | 309.00 |
| EBIT Growth(%) | -6.35 | 140.25 | -4.46 | 13.37 | 610.65 |
| PAT Growth(%) | -32.15 | 159.14 | 56.57 | -20.58 | 221.70 |
| EPS Growth(%) | -28.16 | 87.48 | 8.32 | -71.42 | 221.70 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.64 | 0.82 | 0.55 | 2.21 | 1.12 |
| Current Ratio(x) | 1.33 | 1.35 | 1.39 | 1.03 | 0.94 |
| Quick Ratio(x) | 0.87 | 0.96 | 0.97 | 0.73 | 0.74 |
| Interest Cover(x) | 3.10 | 5.31 | 3.28 | 2.92 | 9.24 |
| Total Debt/Mcap(x) | 0.31 | 0.33 | 0.19 | - | - |
Compare Financial Ratios of peers of SOTAC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOTAC PHARMACEUTICALS | ₹144.3 Cr | 16.4% | 23.3% | -18.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹457,073.0 Cr | 8.1% | 9.3% | 9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹307,147.0 Cr | 10.5% | 18% | 51.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,626.0 Cr | 2.9% | 2.1% | 30.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹115,685.0 Cr | -0.1% | 16% | 14.6% | Stock Analytics | |
| CIPLA | ₹113,589.0 Cr | 1.4% | 8.1% | -6.8% | Stock Analytics | |
SOTAC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOTAC PHARMACEUTICALS | 16.4% |
23.3% |
-18.7% |
| SENSEX | 5.5% |
13.3% |
-3.4% |
You may also like the below Video Courses
